Comparison of finasteride and alpha-blockers as independent risk factors for erectile dysfunction

International Journal of Clinical Practice

Volumn 57, Issue 6, 2003, Pages 484-487

  Sadeghi Nejad, Hossein ^a,b   Sherman, N ^a,b   Lue, J ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; GLIPIZIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENTOLAMINE; PLACEBO; TERAZOSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERECTILE DYSFUNCTION; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM; SMOKING; STATISTICAL SIGNIFICANCE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ENZYME INHIBITORS; FINASTERIDE; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PRAZOSIN; RISK FACTORS;

EID: 0042564563     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Kaplan SA, Reis RB, Kohn IJ et al. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998; 52(5): 739-743.
2. Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adrenergic receptors in erectile function. Int J Impot Res 2000; 12(suppl 1): S48-S63.
3. Kirby RRC, Altwein JE, Bartsch G et al. Impact of prostate size on response to medical therapy for benign prostatic hyperplasia (BPH): results of the PREDICT trial. J Urol 1999; 161: 266. Abstract.
4. Leper H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335(8): 533-539.
5. Rosen RC, Riley A, Wagner G et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49(6): 822-830.
6. Rosen RC, Cappelleri JC, Smith MD et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11(6): 319-326.
7. Shaohua C HJ, Wein AJ, Chacko S, DiSanto ME. The effect of bladder outlet obstruction on rabbit corpus cavernosum smooth muscle contractility. J Urol 2001; 165(suppl 5): 228. Abstract.
8. Muramatsu I, Taniguchi T, Okada K. Tamsulosin: alpha 1-adrenoceptor subtype-selectivity and comparison with terazosin. Jpn J Pharmacol 1998; 78(3): 331-335.
9. Saenz de Tejada I, Kim N, Lagan I et al. Regulation of adrenergic activity in penile corpus cavernosum. J Urol 1989; 142(4): 1117-1121.
10. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338(9): 557-563.
11. Bruskewitz R, Girman CJ, Fowler J et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999; 54(4): 670-678.
12. Kirby R BP, Roehrborn Cc. Results of PREDICT (Prospective European Doxazosin and Combination) study of medical therapy for BPH. Br J Urol Int 1999; 83(suppl 4): 202-204.